AperçuGraphiqueProfilStatistiques clésDonnées financièresActualitésTraderScreen

Biofrontera AG/  DE000A4BGGM7  /

Cboe Europe CXE
-  - Chg. - Volume Bid- Demandez à- Capitalisation boursière Dividende Y. Rapport P/E
-EUR - -
Chiffrre d'affaires: -		 -Bid taille: - -Ask la taille: - 8.37 Mio.EUR - -
GlobeNewswire 14/08 Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire 24/06 Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
GlobeNewswire 10/11/2023 The Benchmark Company Announces Upcoming 12th Annual Discovery One-on-One Investor Conference
GlobeNewswire 09/10/2023 ROTH MKM to Host Healthcare Opportunities Conference on October 12th at the Yale Club in New York Ci...
GlobeNewswire 17/03/2022 Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of De...
GlobeNewswire 14/03/2022 Biofrontera Inc. Announces FDA Orange Book Listing of U.S. Patent for BF-RhodoLED® XL, Extends Prote...
GlobeNewswire 09/03/2022 Biofrontera Inc. to Present at the 34th Annual Roth Conference
GlobeNewswire 07/03/2022 Biofrontera Inc. Appoints Kevin D. Weber to its Board of Directors
GlobeNewswire 14/02/2022 Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs
GlobeNewswire 01/02/2022 Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBC...
GlobeNewswire 18/01/2022 Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the S...
GlobeNewswire 13/01/2022 Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
GlobeNewswire 10/01/2022 Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January
GlobeNewswire 30/12/2021 Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant...
GlobeNewswire 13/12/2021 Biofrontera Inc. Announces Enrollment of First Subject in Phase 2b Clinical Trial Evaluating Ameluz®...
GlobeNewswire 08/12/2021 Biofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lamp
GlobeNewswire 06/12/2021 Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with ...
GlobeNewswire 02/12/2021 Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol
GlobeNewswire 02/12/2021 Biofrontera Inc. Announces Closing of $15 Million Private Placement
GlobeNewswire 30/11/2021 Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
GlobeNewswire 29/11/2021 Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules
GlobeNewswire 23/11/2021 Biofrontera Inc. to Report Third Quarter Financial Results on November 30, 2021
GlobeNewswire 19/11/2021 Biofrontera AG announces mediation results
GlobeNewswire 18/11/2021 The Benchmark Company Announces Its Upcoming 10th Annual One-on-One Discovery Conference
GlobeNewswire 17/11/2021 Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021